✦ LIBER ✦

Pemetrexed for the treatment of non-small cell lung cancer

✍ Scribed by Genova, Carlo; Rijavec, Erika; Truini, Anna; Coco, Simona; Sini, Claudio; Barletta, Giulia; Dal Bello, Maria Giovanna; Alama, Angela; Savarino, Grazia; Pronzato, Paolo; Boccardo, Francesco; Grossi, Francesco

Book ID: 121323867
Publisher: Informa plc
Year: 2013
Tongue: English
Weight: 510 KB
Volume: 14
Category: Article
ISSN: 1465-6566
DOI: 10.1517/14656566.2013.802774

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN20 MAINTENANCE ERLOTINIB VERSUS PEMET

PCN20 MAINTENANCE ERLOTINIB VERSUS PEMETREXED FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER: INDIRECT COMPARISON APPLYING REAL-LIFE OUTCOMES

✍ R Casciano; H Bischoff; M Nuijten; E Malangone; J Ray 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB

33 The use of pemetrexed for the first-l

33 The use of pemetrexed for the first-line treatment of non-small cell lung cancer

✍ Silva, S.; Colquitt, J.; Hatton, M.Q.; Mohanamurali, J.; Lee, C.; Danson, S.; Fi 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Pemetrexed approved for the first-line t

Pemetrexed approved for the first-line treatment of non-small-cell lung cancer: summary of the NICE appraisal

✍ Panagiota Vrouchou; Prashanth Kandaswamy; Elisabeth George; David Barnett 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 58 KB

Vandetanib Plus Pemetrexed for the Secon

Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial

✍ de Boer, R. H.; Arrieta, O.; Yang, C.-H.; Gottfried, M.; Chan, V.; Raats, J.; de 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 295 KB

Cost-effectiveness analysis of pemetrexe

Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population

✍ Yumi Asukai; Amparo Valladares; Carlos Camps; Eifiona Wood; Kaisa Taipale; Jorge 📂 Article 📅 2010 🏛 BioMed Central 🌐 English ⚖ 781 KB

PARAMOUNT: Final Overall Survival Result

PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer

✍ Paz-Ares, Luis G. (author);De Marinis, Filippo (author);Dediu, Mircea (author);T 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 209 KB